Somatostatin treatment of a persistent chyloperitoneum following abdominal aortic surgery.

Abstract

Chyloperitoneum is an uncommon but serious complication of abdominal aortic surgery. There are no optimal guidelines for the management of chyloperitoneum. We present here our experiences regarding the treatment of chyloperitoneum with somatostatin for three patients who underwent surgery for abdominal aortic disease. Milky, odorless liquid was observed in the abdominal drain of these patients. The conservative treatment with total parenteral nutrition failed; therefore, in parallel, we initiated a somatostatin treatment as a continuous perfusion. Drain loss decreased in all up to the second day of treatment. The probable mechanisms of the somatostatin decrease the intestinal absorption of fats via the specific receptors, decrease triglyceride concentration in the thoracic duct, and attenuate lymph flow in the major lymphatic channels. The presented cases showed successful treatment using somatostatin and may be a new generation of effective treatments for chyloperitoneum.

• Authors: Saziye Karaca, Gino Gemayel, Afksendiyos Kalangos
• Journal: Journal of vascular surgery (J Vasc Surg) Vol. 56 Issue 5 Pg. 1409-12 (Nov 2012) ISSN: 1097-6809 [Electronic] United States
• PMID: 22999046 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Chemical References

• Hormones
• Somatostatin

Topics

• Aged, 80 and over
• Aorta, Abdominal (surgery)
• Aortic Aneurysm, Abdominal (surgery)
• Aortic Coarctation (surgery)
• Chylous Ascites (drug therapy)
• Female
• Hormones (therapeutic use)
• Humans
• Postoperative Complications (drug therapy)
• Somatostatin (therapeutic use)